SCHEMBL1703442

SCHEMBL1703442

Cc1ccccc1-n1c(CCl)nc2ccsc2c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.57
ALDH1A1 P00352 6/20 0.47
POLB P06746 2/20 0.47
PDE4B Q07343 3/20 0.46
PDE7A Q13946 3/20 0.46
PDE4D Q08499 2/20 0.46
PDE4A P27815 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PDE10A Q9Y233 1/20 0.42
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
MALT1 Q9UDY8 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242198 0.88 PIK3CD (0.56) PIK3CDALDH1A1POLBPDE4BPDE7A
SCHEMBL4242355 0.83 PIK3CD (0.57) PIK3CDALDH1A1POLBPDE4BPDE7A
SCHEMBL6222959 0.83 ALDH1A1 (0.63) PIK3CDALDH1A1POLBPDE4BPDE7A
SCHEMBL7512190 0.81 PIK3CD (0.54) PIK3CDALDH1A1POLBPDE4BPDE7A
SCHEMBL7509324 0.81 PIK3CD (0.52) PIK3CDALDH1A1POLBPDE4BPDE7A
SCHEMBL1703503 0.80 ALDH1A1 (0.70) PIK3CDALDH1A1PDE7APDE4DSMN1; SMN2
SCHEMBL4393433 0.79 ALDH1A1 (0.68) PIK3CDALDH1A1PDE7APDE4DSMN1; SMN2
SCHEMBL1703426 0.79 PIK3CD (0.47) PIK3CDALDH1A1POLBPDE4BPDE7A
SCHEMBL735504 0.78 PIK3CD (0.73) PIK3CDALDH1A1PDE10ALMNAL3MBTL1
SCHEMBL1703695 0.76 PIK3CD (0.49) PIK3CDALDH1A1POLBPDE4BPDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441768-A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers Eli Lilly & Co. (US) 2012-04-18 EP disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
EP-2097422-A1 THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS Eli Lilly & Co. (US) 2009-09-09 EP disclosed
WO-2008064018-A1 THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ELI LILLY & CO. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS PIK3CA, PIK3CD, PIK3CB PIK3CD 2/4885ALDH1A1 1821/4885POLB 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.